Alcon announces Neurotech Pharmaceuticals acquisition
The deal combines Neurotech's platform with Alcon's expertise to advance retinal disease treatment access and innovation.
See the latest news and media coverage for Alcon. We track all announcements, press releases, and industry mentions in real time, all in one place.
Eye care company specializing in surgical and vision care products
alcon.comLast updated
In short: Alcon acquired Neurotech for $550 million, beat Q2 expectations, and raised its 2026 guidance.
The deal combines Neurotech's platform with Alcon's expertise to advance retinal disease treatment access and innovation.
The new over-the-counter relief product works in one minute with results lasting up to 12 hours from a single drop. It joins the company's expanding portfolio.
The new product is now commercially available, showcased during the London conference to highlight surgical innovations and future eye care advancements.
The debt carries a 3.875 percent interest rate and matures in 2033. Proceeds will fund general corporate purposes and refinance existing obligations.
The newspaper for business news, background analyses, currency and stock prices, as well as investment recommendations.
The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness relief. 1,2 According to Alcon, each dose whitens the...
Alcon's Q2 2026 core earnings per share reached USD 0.84, up 10.5 percent from the year-ago quarter and 9.09 percent above the consensus estimate, The...
The Alcon stock benefits from robust results from the second quarter of 2026 with growing operating profit. The price of the Alcon stock is near the middle on 09/20/2026...
Track Alcon and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Alcon and other trending companies.